Figure 2.
circAMOTL1L inhibits cell proliferation and promotes apoptosis in vitro and suppresses tumor growth in vivo. (a) qRT-PCR examined the circAMOTL1L expression level in 786-O and Caki-1 cells after transfecting with pcDNA-circAMOTL1L or vector control. ∗∗∗p < 0.001 vs. vector control. (b) CCK-8 assay examined the proliferation of 786-O and Caki-1 cells transfected with pcDNA-circAMOTL1L or vector control. ∗p < 0.05 vs. vector control. (c) TUNEL assay detected apoptosis of 786-O and Caki-1 cells after transfecting with pcDNA-circAMOTL1L or vector control. ∗∗p < 0.01 vs. vector control (scale bars = 50 μm). The above graph bars represent mean ± SEM of three independent experiments. (d, e) Representative dissected xenograft tumors from nude mice subcutaneously injected with 786-O cells engineered to stably overexpress circAMOTL1L (LV-circAMOTL1L) for 3 weeks (LV-Ctl as the negative control) and corresponding weight measurement. ∗∗p < 0.01 vs. LV-Ctl. (f) qRT-PCR examined PCNA and P53 expression in xenograft tumors. ∗p < 0.05, ∗∗p < 0.01 vs. LV-Ctl (n = 6 in each group). (g, h) The Pearson correlation analyzed the relationship between PCNA mRNA and circAMOTL1L (p < 0.01, r = −0.41) and P53 mRNA and circAMOTL1L (p < 0.01, r = 0.508).